Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Exocrine Pancreatic Insufficiency

Exocrine Pancreatic Insufficiency

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Exocrine Pancreatic Insufficiency

23 trials tracked for Exocrine Pancreatic Insufficiency: 16 in phase 3 or 4 and 1 with published results. The most-cited published study has 43 citations.

23Trials tracked
16Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 4 Phase 3 12 Phase 2 3 Phase 1 1 Other / NA 3
  1. Phase 3 SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis Completed · 43 cited
  2. Phase 4 EASY: Extended Access to Sollpura Over Years Completed
  3. Phase 4 A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of Age Completed
  4. Phase 4 PR-018: An Open-Label, Safety Extension of Study PR-011 Completed
  5. Phase 4 Control of Steatorrhea in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency Completed
  6. Phase 3 SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis Completed
Show 17 more trials
  1. Phase 3 Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency (PEI) Due to Cystic Fibrosis (CF) Completed
  2. Phase 3 Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea Completed
  3. Phase 3 A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI) Completed
  4. Phase 3 Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency Completed
  5. Phase 3 Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency Completed
  6. Phase 3 Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis Completed
  7. Phase 3 A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy Completed
  8. Phase 3 Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI) Completed
  9. Phase 3 Evaluation of Safety and Tolerability of Creon Micro in Children Younger Than Four Years With Pancreatic Exocrine Insufficiency Completed
  10. Phase 3 A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency Completed
  11. Phase 2 A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEI Completed
  12. Phase 2 Study to Assess an Enteric Microgranule Formulation of Adrulipase in Patients With Cystic Fibrosis Completed
  13. Phase 2 Efficacy of Bucelipase Alfa (BSSL) in Patients With Cystic Fibrosis and Pancreatic Insufficiency Completed
  14. Phase 1 Phase 1 Study to Assess Safety and Efficacy of ANG003 Completed
  15. N/A Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis Completed
  16. N/A Special Investigation of LipaCreon on Long-term Use in Patients With Pancreatic Exocrine Insufficiency Completed
  17. N/A Safety, Tolerability and Fat Absorption Using Enteral Feeding In-line Enzyme Cartridge (Relizorb) Completed

Showing the 23 most-cited and recently-updated of 23 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Escherichia-Shigella expansion, reduced diversity distinguish T3cDM gut microbiome from T1DM
Diabetes & Endocrinology
Escherichia-Shigella expansion, reduced diversity distinguish T3cDM gut microbiome from T1DM Could gut bacteria reveal a hidden cause of diabetes? Study finds specific microbes linked to pancreatic damage
A study of 48 outpatients found the gut microbiome in type 3c diabetes (T3cDM) had reduced α-diversity and distinct β-diversity compared to …
A damaged pancreas may directly reshape gut bacteria, causing distinct microbial changes in type 3c diabetes that differ from other forms.
Frontiers Mar 30, 2026